“Clears acne and helps prevent new breakouts from forming.”
CeraVe backs both promises with the same active ingredient: 2% salicylic acid.
There is no pause between them on the US product page. No suggestion that one might rest on stronger evidence than the other.
The first promise did have some clinical support.
In people with mild to moderate acne, a twice-daily treatment containing 2% salicylic acid reduced lesion counts compared with placebo.
But the study used pads impregnated with a 2% salicylic-acid lotion, not CeraVe Acne Control Gel. And it showed fewer lesions, not complete clearance.
Free weekly newsletter
Get every new investigation directly in your inbox.
Science Checks and Brand Checks across the anti-ageing industry — delivered free.
Under the conditions studied, 2% topical salicylic acid can improve existing acne. It does not show how CeraVe’s current gel performs on its own.
Prevention is a different test.
To support “helps prevent new breakouts from forming,” a study would need to measure new breakouts, not just changes in acne already present.
The studies FG reviewed did not. Nor did FG find any eligible public clinical study of the CeraVe gel that measured prevention.
That leaves CeraVe’s sentence resting on two different levels of evidence.
The distinction is easy to lose inside six words: “helps prevent new breakouts from forming.”
FG found clinical support for treating existing acne with 2% salicylic acid. It did not find an eligible public clinical study showing that this gel prevents new breakouts.
